Page last updated: 2024-08-26

mci 9038 and Liver Dysfunction

mci 9038 has been researched along with Liver Dysfunction in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (83.33)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chandler, W; Hart, SR; Liebl, MG; Putney, D; Wanat, MA	1
Albert, M; Boulanger, I; Grégoire, G; Tardif, M; Williamson, DR	1
Hursting, MJ; Levine, RL; McCollum, D	1
Bein, B; Brand, PA; Egberts, JH; Scholz, J; Weiler, N	1
Boer, K; Deufel, T; Kiehntopf, M; Poeschel, K; Siegmund, R; Wolf, G	1
Hursting, MJ; Swan, SK	1

Trials

1 trial(s) available for mci 9038 and Liver Dysfunction

Article	Year
The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy, 2000, Volume: 20, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Area Under Curve; Arginine; Female; Humans; Kidney; Kidney Diseases; Liver; Liver Diseases; Male; Middle Aged; Minnesota; Pipecolic Acids; Prospective Studies; Quebec; Sex Factors; Sulfonamides; Texas	2000

Article

Year

The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.

Pharmacotherapy, 2000, Volume: 20, Issue:3

Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Area Under Curve; Arginine; Female; Humans; Kidney; Kidney Diseases; Liver; Liver Diseases; Male; Middle Aged; Minnesota; Pipecolic Acids; Prospective Studies; Quebec; Sex Factors; Sulfonamides; Texas

2000

Other Studies

5 other study(ies) available for mci 9038 and Liver Dysfunction

Article	Year
Alternative monitoring of argatroban using plasma-diluted thrombin time. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:4 Topics: Aged, 80 and over; Arginine; Drug Monitoring; Humans; Liver Diseases; Male; Pipecolic Acids; Sulfonamides; Thrombin Time; Thrombocytopenia	2013
Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy, 2004, Volume: 24, Issue:3 Topics: Acute Kidney Injury; Aged; Arginine; Critical Care; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heparin; Humans; Infusions, Parenteral; International Normalized Ratio; Liver Diseases; Male; Middle Aged; Partial Thromboplastin Time; Pipecolic Acids; Renal Replacement Therapy; Sulfonamides; Thrombocytopenia; Transaminases	2004
Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest, 2006, Volume: 129, Issue:5 Topics: Aged; Anticoagulants; Arginine; Bilirubin; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Liver Diseases; Male; Middle Aged; Partial Thromboplastin Time; Pipecolic Acids; Platelet Aggregation Inhibitors; Retrospective Studies; Sulfonamides; Thrombocytopenia; Thrombosis; Treatment Outcome	2006
Argatroban therapy in patients with hepatic and renal impairment. European journal of anaesthesiology, 2008, Volume: 25, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Arginine; Critical Care; Critical Illness; Dose-Response Relationship, Drug; Female; Humans; Liver Diseases; Male; Pipecolic Acids; Postoperative Complications; Sulfonamides	2008
Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2008, Volume: 19, Issue:4 Topics: Anticoagulants; Arginine; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Humans; In Vitro Techniques; Liver Diseases; Pipecolic Acids; Platelet Aggregation Inhibitors; Sulfonamides	2008